Literature DB >> 20030417

Role of antiepileptic drugs as preventive agents for migraine.

Michail Vikelis1, Alan M Rapoport.   

Abstract

Migraine is a common neurological disease affecting about 12% of the population in Western Europe and North America, and causing a considerable burden both to migraineurs and to society. Severe, frequent and disabling migraine attacks, as well as those poorly responsive to acute care medication, require preventive treatment, which is often under-utilized. Antiepileptic drugs are used in the prevention of migraine. We performed a literature search of PubMed through June 2008 for controlled trials of antiepileptic drugs in the prevention of migraine. The search identified 70 papers for a full-text review. The majority of these papers referred to valproate and topiramate, and showed that these drugs are effective and well tolerated in migraine prevention and are suitable for first-line clinical use. On the other hand, acetazolamide, lamotrigine, oxcarbazepine and vigabatrin have been shown to be not effective and gabapentin requires further evaluation. For the rest of the antiepileptic drugs, no data from controlled trials are available.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20030417     DOI: 10.2165/11310970-000000000-00000

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  79 in total

1.  Lamotrigine versus placebo in the prophylaxis of migraine with and without aura.

Authors:  T J Steiner; L J Findley; A W Yuen
Journal:  Cephalalgia       Date:  1997-04       Impact factor: 6.292

2.  Topiramate for migraine prevention in adolescents: a pooled analysis of efficacy and safety.

Authors:  Paul Winner; Astrid Gendolla; Catherine Stayer; Steven Wang; Eric Yuen; Wendy P Battisti; Jeffrey S Nye
Journal:  Headache       Date:  2006 Nov-Dec       Impact factor: 5.887

3.  Lamotrigine in the prophylactic treatment of migraine aura--a pilot study.

Authors:  C Lampl; A Buzath; D Klinger; K Neumann
Journal:  Cephalalgia       Date:  1999-01       Impact factor: 6.292

4.  Prevalence and burden of migraine in the United States: data from the American Migraine Study II.

Authors:  R B Lipton; W F Stewart; S Diamond; M L Diamond; M Reed
Journal:  Headache       Date:  2001 Jul-Aug       Impact factor: 5.887

5.  Impact of topiramate migraine prophylaxis on workplace productivity: results from two US randomized, double-blind, placebo-controlled, multicenter trials.

Authors:  Jennifer H Lofland; Joshua J Gagne; Laura T Pizzi; Marcia Rupnow; Stephen D Silberstein
Journal:  J Occup Environ Med       Date:  2007-03       Impact factor: 2.162

6.  Topiramate in the treatment of chronic migraine.

Authors:  M Silvestrini; M Bartolini; M Coccia; R Baruffaldi; R Taffi; L Provinciali
Journal:  Cephalalgia       Date:  2003-10       Impact factor: 6.292

7.  Topiramate for patients with refractory migraine: an observational, multicenter study in Spain.

Authors:  J Pascual; M Sánchez del Rio; V Mateos; J M Láinez; J Hernández-Gallego; R Leira; M D Jiménez
Journal:  Neurologia       Date:  2003-09       Impact factor: 3.109

8.  Divalproex extended-release in adolescent migraine prophylaxis: results of a randomized, double-blind, placebo-controlled study.

Authors:  George Apostol; Roger K Cady; Genevieve A Laforet; Weining Z Robieson; Evelyn Olson; Walid M Abi-Saab; Mario Saltarelli
Journal:  Headache       Date:  2008-07       Impact factor: 5.887

9.  A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis.

Authors:  Frederick G Freitag; S D Collins; H A Carlson; J Goldstein; J Saper; S Silberstein; N Mathew; P K Winner; R Deaton; K Sommerville
Journal:  Neurology       Date:  2002-06-11       Impact factor: 9.910

10.  A double-blind, dose comparison study of topiramate for prophylaxis of basilar-type migraine in children: a pilot study.

Authors:  Donald Lewis; Erika Paradiso
Journal:  Headache       Date:  2007 Nov-Dec       Impact factor: 5.887

View more
  13 in total

Review 1.  [Chronic migraine].

Authors:  H C Diener; D Holle; D Müller; S Nägel; K Rabe
Journal:  Nervenarzt       Date:  2013-12       Impact factor: 1.214

2.  Topiramate related reversible erectile dysfunction in temporal lobe epilepsy.

Authors:  Ling-Chien Hung; Julie Chi Chow; Chia-Yen Chang; Jing-Jane Tsai; Chin-Wei Huang
Journal:  Neurol Sci       Date:  2011-07-09       Impact factor: 3.307

3.  Migraine, stroke and epilepsy: underlying and interrelated causes, diagnosis and treatment.

Authors:  Aida Rodriguez-Sainz; Ana Pinedo-Brochado; Jose L Sánchez-Menoyo; Javier Ruiz-Ojeda; Ines Escalza-Cortina; Juan Carlos Garcia-Monco
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-06

Review 4.  Migraine prophylaxis: what is new and what we need?

Authors:  P Barbanti; C Aurilia; G Egeo; L Fofi
Journal:  Neurol Sci       Date:  2011-05       Impact factor: 3.307

5.  Efficacy of combined topiramate/thioctic acid therapy in migraine prophylaxis.

Authors:  Ahmed M Ali; Thanaa G Awad; Nagwa M Al-Adl
Journal:  Saudi Pharm J       Date:  2010-07-30       Impact factor: 4.330

6.  Sodium valproate exposure during the brain growth spurt transiently impairs spatial learning in prepubertal rats.

Authors:  Cláudio C Filgueiras; Fernanda Pohl-Guimarães; Thomas E Krahe; Alexandre E Medina
Journal:  Pharmacol Biochem Behav       Date:  2012-11-21       Impact factor: 3.533

7.  Preventive agents for migraine: focus on the antiepileptic drugs.

Authors:  R Shahien; K Beiruti
Journal:  J Cent Nerv Syst Dis       Date:  2012-02-26

8.  Efficacy and tolerability of pregabalin as preventive treatment for migraine: a 3-month follow-up study.

Authors:  Raffaella Pizzolato; Veronica Villani; Luca Prosperini; Alessandro Ciuffoli; Giuliano Sette
Journal:  J Headache Pain       Date:  2011-04-09       Impact factor: 7.277

9.  The effects of body mass index on the treatment of the patients with migraine headaches.

Authors:  Siamak Afshinmajd; Ali Davati; Farnaz Akbari
Journal:  Iran J Neurol       Date:  2011

10.  Italian guidelines for primary headaches: 2012 revised version.

Authors:  Paola Sarchielli; Franco Granella; Maria Pia Prudenzano; Luigi Alberto Pini; Vincenzo Guidetti; Giorgio Bono; Lorenzo Pinessi; Massimo Alessandri; Fabio Antonaci; Marcello Fanciullacci; Anna Ferrari; Mario Guazzelli; Giuseppe Nappi; Grazia Sances; Giorgio Sandrini; Lidia Savi; Cristina Tassorelli; Giorgio Zanchin
Journal:  J Headache Pain       Date:  2012-05       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.